Home » Stocks » Organogenesis Holdings

Organogenesis Holdings, Inc. (ORGO)

Stock Price: $3.64 USD 0.00 (0.00%)
Updated Jul 6, 2020 4:00 PM EDT - Market open

Stock Price Chart

Key Info

Market Cap 386.23M
Revenue (ttm) 265.59M
Net Income (ttm) -41.10M
Shares Out 106.11M
EPS (ttm) -0.43
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Jul 6, 2020
Last Price $3.64
Previous Close $3.64
Change ($) 0.00
Change (%) 0.00%
Day's Open -
Day's Range 3.60 - 3.86
Day's Volume 475
52-Week Range 2.47 - 8.34

More Stats

Market Cap 386.23M
Enterprise Value 449.16M
Earnings Date (est) Aug 10, 2020
Ex-Dividend Date n/a
Shares Outstanding 106.11M
Float 11.61M
EPS (basic) -0.43
EPS (diluted) -0.43
FCF / Share -0.49
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 244,254
Short Ratio 0.69
Short % of Float 0.58%
Beta n/a
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 1.45
PB Ratio 10.19
Revenue 265.59M
Operating Income -32.39M
Net Income -41.10M
Free Cash Flow -51.41M
Net Cash -62.93M
Net Cash / Share -0.59
Gross Margin 69.67%
Operating Margin -12.19%
Profit Margin -15.70%
FCF Margin -19.36%
ROA -10.53%
ROE -112.83%
ROIC -20.40%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (4)

Buy 4
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$7.50*
(106.04% upside)
Low
7.00
Current: 3.64
High
8.00
Target: 7.50
*Average 12-month price target from 4 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016
Revenue261193199139
Revenue Growth34.91%-2.55%43.09%-
Gross Profit18512513790.53
Operating Income-29.45-47.90-5.50-8.78
Net Income-40.45-64.83-8.39-16.99
Shares Outstanding92.8469.3263.8863.20
Earnings Per Share-0.44-0.94-0.14-0.27
Operating Cash Flow-33.53-60.64-3.49-4.87
Capital Expenditures-6.23-1.86-2.42-1.25
Free Cash Flow-39.76-62.49-5.91-6.12
Cash & Equivalents60.3721.412.36311
Total Debt10159.261020.43
Net Cash / Debt-40.24-37.86-99.98311
Assets221164149311
Liabilities16511715711.33
Book Value55.5847.04-15.325.00
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Organogenesis Holdings, Inc.
Country United States
Employees 835
CEO Gary S. Gillheeney

Stock Information

Ticker Symbol ORGO
Stock Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Unique Identifier NASDAQ: ORGO

Description

Organogenesis Holdings Inc., a regenerative medicine company, focuses on the development, manufacture, and commercialization of solutions for the advanced wound care, and surgical and sports medicine markets primarily in the United States. The company's advanced wound care products include Apligraf for the treatment of venous leg ulcers and diabetic foot ulcers (DFUs); Dermagraft for treating DFUs; PuraPly AM to address biofilm across a range of wound types; and Affinity and NuShield to address various wound sizes and types. Its surgical and sports medicine products comprise ReNu for in-office joint and tendon applications; NuCel for bony fusion in the spine and extremities; NuShield and Affinity for surgical applications in targeted soft tissue repairs; and PuraPly AM for the surgical treatment of open wounds. The company's pipeline products include TransCyte for the treatment of second- and third-degree burns; PuraForce, a bioengineered porcine collagen surgical matrix for use in soft tissue reinforcement applications; Novachor for the treatment of chronic and acute wounds; Gintuit for the treatment of mucogingival conditions in adults; and PuraPly XT and PuraPly MZ for the treatment of chronic and acute wounds, as well as for surgical treatment of open wounds. It serves hospitals, wound care centers, government facilities, ambulatory service centers, and physician offices. The company sells its products through direct sales representatives and independent agencies. Organogenesis Holdings Inc. was founded in 1985 and is headquartered in Canton, Massachusetts.